

DAFTAR PUSTAKA

1. Martindale: The Complete Drug Reference. 36th ed. London: Pharmaceutical Press;
2. DrugBank. Celecoxib [Internet]. Drugbank. [cited 2019 Jun 12]. Available from: <https://www.drugbank.ca/drugs/DB00482>
3. Pubchem. Celcoxib [Internet]. National Center for Biotechnology Information. [cited 2019 Jun 12]. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/Celecoxib>
4. Moffat AC, Osselton MD, Widdop B, Watts J. Clarke's Analysis of Drugs and Poisons. London: Pharmaceutical Press; 2011.
5. Almansa C, Mercè R, Tesson N, Farran J, Tomàs J, Plata-Salamán CR. Co-crystal of Tramadol Hydrochloride-Celecoxib (ctc): A Novel API-API Co-crystal for the Treatment of Pain. *Cryst Growth Des.* 2017;17(4):1884–92.
6. Jouyban-Gharamaleki V, Soleymani J, Jouyban-Gharamaleki K, Suleymanov TA, Jouyban A. Solubilization of celecoxib, lamotrigine and phenytoin using ethanol and a nonionic surfactant. *J Mol Liq* [Internet]. 2017;243:715–9.
7. Jouyban A, Nozohouri S, Martinez F. Solubility of celecoxib in {2-propanol (1) + water (2)} mixtures at various temperatures: Experimental data and thermodynamic analysis. *J Mol Liq* [Internet]. 2018;254(1):1–7.
8. Bolla G, Mittapalli S, Nangia A. Celecoxib cocrystal polymorphs with cyclic amides: Synthons of a sulfonamide drug with carboxamide cofomers. *CrystEngComm.* 2014;16(1):24–7.
9. He G, Chow PS, Tan RBH. Predicting Multicomponent Crystal Formation : The Interplay between Homomeric and Heteromeric Interactions. 2009;
10. Berry DJ, Steed JW. Pharmaceutical cocrystals, salts and multicomponent systems; intermolecular interactions and property based design. *Adv Drug Deliv Rev* [Internet]. 2017;117:3–24.
11. Rodrigues M, Baptista B, Lopes JA, Sarraguça MC. Pharmaceutical cocrystallization techniques . Advances and challenges. *Int J Pharm* [Internet]. 2018;547(1–2):404–20.

12. Korotkova EI, Kratochvíl B. Pharmaceutical Cocrystals. *Procedia Chem* [Internet]. 2014;10(3822):473–6.
13. J W, L Q. *Pharmaceutical Salts and Co-crystals*. 2012; Available from: <http://ebook.rsc.org/?DOI=10.1039/9781849733502>
14. Remenar JF, Peterson ML, Stephens PW, Zhang Z, Zimenkov Y, Hickey MB. Celecoxib:Nicotinamide Dissociation: Using Excipients To Capture the Cocrystal's Potential. 2007;3(6):2381–92.
15. Hussain Z, Chaudhri VK, Pandey A, Srivastava AK, Maurya R, Pradesh U. Isolation and evaluation of piperine from black. 2017;6(8):1424–30.
16. Gorgani L, Mohammadi M, Najafpour GD, Nikzad M. Piperine — The Bioactive Compound of Black Pepper: From Isolation to Medicinal Formulations. 2016;00:1–17.
17. Vasavirama K, Upender M. Piperine : A valuable alkaloid from piper species *Innovare*. 2014;(September).
18. Pubchem. Piperine [Internet]. National Center for Biotechnology Information. [cited 2019 Jun 13]. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/Piperine#section=Chemical-and-Physical-Properties>
19. US Environmental Protection Agency. Biopesticides registration action document oil of black pepper: Piperine. United States;
20. Vioglio PC, Chierotti MR, Gobetto R. Pharmaceutical aspects of salt and cocrystal forms of APIs and characterization challenges. *Adv Drug Deliv Rev* [Internet]. 2017;117:86–110.
21. Chemical C. Product information. United States; 2018.
22. Aguiar CPO, Lopes DCF, Borges RS. Influence of piperidine ring on stability and reactivity of piperine. *Chem Data Collect* [Internet]. 2018;17–18:138–42.
23. Wang R, Han J, Jiang A, Huang R, Fu T, Wang L, et al. Involvement of metabolism-permeability in enhancing the oral bioavailability of curcumin in excipient-free solid dispersions co-formed with piperine. *Int J Pharm* [Internet]. 2019;561:9–18.
24. Janakiraman K, Nadu T. Compatibility and stability studies of ampicillin trihydrate and piperine mixture. *Int J Pharm Res*. 2011;2(5):1176–81.
25. Sharma S, Kalia NP, Suden P, Chauhan PS, Kumar M, Ram AB, et al.

- Protective efficacy of piperine against *Mycobacterium tuberculosis*. *Tuberculosis* [Internet]. 2014;94(4):389–96.
26. Mohammed E. Azzouz, Yuan Chen, Hasnaa M. Hassan, Shivangi Agarwal, Aravind Pai MBS. Preparation and solid state characterisation of co-crystals of etravirine engineered by fabricating with flavonoids as possible conformers. *Lat Am J Pharm* [Internet]. 2018;37(9):1784–90.
 27. Grothe E, Meekes H, Vlieg E, Ter Horst JH, De Gelder R. Solvates, Salts, and Cocrystals: A Proposal for a Feasible Classification System. *Cryst Growth Des*. 2016;16(6):3237–43.
 28. Marie A, Ayenew Z, Kumar D, Madi AM. Pharmaceutical solvates, hydrates and amorphous forms: A special emphasis on cocrystals ☆. *Adv Drug Deliv Rev* [Internet]. 2017;117:25–46.
 29. Stephen M, Lyle D, Donald C. Pharmaceutical Salts. *J Pharm Sci*. 1977;66(1):1–19.
 30. Childs SL, Stahly GP, Park A. The salt-cocrystal continuum: The influence of crystal structure on ionization state. *Mol Pharm*. 2007;4(3):323–38.
 31. Healy AM, Worku ZA, Kumar D, Madi AM. Pharmaceutical solvates, hydrates and amorphous forms: A special emphasis on cocrystals. *Adv Drug Deliv Rev* [Internet]. 2017;117:25–46.
 32. Aaltonen J, Allesø M, Mirza S, Koradia V, Gordon KC, Rantanen J. Solid form screening - A review. *Eur J Pharm Biopharm* [Internet]. 2009;71(1):23–37.
 33. Khankari RK, Grant DJW. Pharmaceutical hydrates. *Thermochim Acta*. 1995;248(C):61–79.
 34. FDA. Guidance for Industry: Regulatory Classification of Pharmaceutical Cocrystals. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 2011.
 35. Patole T, Deshpande A. Co-Crystallization-a Technique for Solubility Enhancement. *Int J Pharm Sci Res*. 2014;5(9):3566–76.
 36. Beckmann W, Nickisch K, Budde U. Development of a Seeding Technique for the Crystallization of the Metastable A Modification of Abecarnil Abstract : 1998;6160(6): 298-304.
 37. Rehder S, Klukkert M, Löbmann KAM, Strachan CJ, Sakmann A, Gordon K, et al. Investigation of the formation process of two piracetam cocrystals

during grinding. *Pharmaceutics*. 2011;3(4):706–22.

38. Susanti M, Dachriyanus. *Kromatografi Cair Kinerja Tinggi*. Padang: LPTIK Universitas Andalas;
39. Vander Heyden Y, Nijhuis A, Smeyers-Verbeke J, Vandeginste BGM, Massart DL. Guidance for robustness/ruggedness tests in method validation. *J Pharm Biomed Anal*. 2001;24(5–6):723–53.
40. Qiao N, Li M, Schlindwein W, Malek N, Davies A, Trappitt G. Pharmaceutical cocrystals: An overview. *Int J Pharm* [Internet]. 2011;419(1–2):1–11.
41. Elder DP, Holm R, Lopez H, Diego D. Use of pharmaceutical salts and cocrystals to address the issue of poor solubility. *Int J Pharm* [Internet]. 2012;
42. Departemen Kesehatan RI. *Farmakope Indonesia*. Kelima. Jakarta: Departemen Kesehatan RI; 2014.
43. Halasz I, Kimber SAJ, Beldon PJ, Belenguer AM, Adams F, Honkimäki V, et al. In situ and real-time monitoring of mechanochemical milling reactions using synchrotron X-ray diffraction. *Nat Protoc*. 2013;8(9):1718–29.
44. Cho KH, Jee J, Yang DA, Kim ST, Kang D, Kim D, et al. Improved Dissolution and Oral Bioavailability of Celecoxib by a Dry Elixir System. 2018;1482–6.
45. Pfizer. Product Monograph: Celecoxib [Internet]. Pfizer. 2017 [cited 2019 Dec 2]. Available from: <https://www.pfizer.ca/pm/en/celecoxib.pdf>
46. Zaini E, Nisak RK, Utami RD, Fitriani L, Ismed F. Effect of Milling on Physicochemical Properties of Usnic acid Isolated from *Usnea* sp. *Oriental Journal of Chemistry*. 2017;2–7
47. Friščič T, Jones W. Recent advances in understanding the mechanism of cocrystal formation via grinding. *Cryst Growth Des*. 2009;9(3):1621–37.
48. Banga S, Chawla G, Varandani D, Mehta BR, Bansal AK. Modification of the crystal habit of celecoxib for improved processability. *J Pharm Pharmacol*. 2007;59(1):29–39.
49. Digarse H, Sarkar D. Production of the metastable δ -polymorphic form of pyrazinamide by isothermal internal seeding anti-solvent crystallization. *J Cryst Growth* [Internet]. 2019;526(September):125245.
50. Malamatari M, Ross SA, Douroumis D, Velaga SP. Experimental cocrystal

- screening and solution based scale-up cocrystallization methods ☆. *Adv Drug Deliv Rev* [Internet]. 2017;
51. Zaini E, Sumirtapura YC, Soewandhi SN, Halim A, Uekusa H, Fujii K. Cocrystalline phase transformation of binary mixture of trimethoprim and sulfamethoxazole by slurry technique. *Asian J Pharm Clin Res*. 2010;3:26–9.
 52. Zaini E, Rachmaini F, Armin F, Fitriani L. Preparation and Characterization of Binary Mixture of Efavirenz and Nicotinamide. *Oriental Journal of Chemistry*. 2015; 31:2271-2276
 53. Zaini E, Sumirtapura YC, Halim A, Fitriani L, Soewandhi SN. Formation and Characterization of Sulfamethoxazole-Trimethoprim Cocrystal by Milling Process. 2018;7:169-173.
 54. Baird JA, Taylor LS. Evaluation of amorphous solid dispersion properties using thermal analysis techniques. *Adv Drug Deliv Rev* [Internet]. 2012;64(5):396–421.
 55. Nakakuki S. NII-Electronic Library Service. *Chem Pharm Bull*. 1986;34(1):430–3.
 56. Stott PW, Williams AC, Barry BW. Transdermal delivery from eutectic systems: enhanced permeation of a model drug, ibuprofen. 1998;50:297–308.
 57. Harnita. Petunjuk pelaksanaan validasi. *Majalah Ilmu Kefarmasian*. 2004;I(3):117–35.
 58. UNODC. Guidance for the validation of analytical methodology and calibration of equipment used for testing of Illicit drugs in seized materials and biological specimens. New york: United Nations; 2009.
 59. Biopharm International. Establishing Acceptance Criteria for Analytical Methods.; 2016
 60. Paithankar H. HPLC Method Validation for Pharmaceuticals: a review. *International journal of universal pharmacy and bio sciences*. 2014; 2: 229-240.
 61. Savjani KT, Gajjar AK, Savjani JK. Drug solubility: Importance and enhancement techniques. *Int Sch Res Netw Pharm*. 2012;2012:1–10.
 62. Kumar S, Nanda A. Pharmaceutical Cocrystal : An Overview. *Indian J Pharm Sci*. 2017;79(6).